Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentina Boni

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Oncology|March 30, 2021
A Predictive Score of Antitumour Activity of Novel Agents in Cancer Patients Treated in Early Phase StudiesRunhan Liu, Ana Gomes, Geriletu Ao, et al.
Investigational New Drugs|July 21, 2021
Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studiesGeriletu Ao, Maria de Miguel, Ana Gomes, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trialEmiliano Calvo, Valentina Boni, Olivier Dumas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2019
Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8]Anas Gazzah, Valentina Boni, Jean-Charles Soria, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2018
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumoursAnas Gazzah, Valentina Boni, Jean-Charles Soria, et al.
Stem Cells (Dayton, Ohio)|September 29, 2011
MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cellsNerea Bitarte, Eva Bandres, Valentina Boni, et al.
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Investigational New Drugs|November 23, 2016
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumorsLuis Paz-Ares, Martin Forster, Valentina Boni, et al.
Cancers|July 24, 2021
Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast CancerJosé Manuel López-Vega, Isabel Álvarez, Antonio Antón, et al.
The Oncologist|September 15, 2021
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 TrialAnna Minchom, Aaron C Tan, Erminia Massarelli, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Oncology|March 30, 2021
A Predictive Score of Antitumour Activity of Novel Agents in Cancer Patients Treated in Early Phase StudiesRunhan Liu, Ana Gomes, Geriletu Ao, et al.
Investigational New Drugs|July 21, 2021
Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studiesGeriletu Ao, Maria de Miguel, Ana Gomes, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trialEmiliano Calvo, Valentina Boni, Olivier Dumas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2019
Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8]Anas Gazzah, Valentina Boni, Jean-Charles Soria, et al.
European Journal of Cancer (Oxford, England : 1990)|October 3, 2018
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumoursAnas Gazzah, Valentina Boni, Jean-Charles Soria, et al.
Stem Cells (Dayton, Ohio)|September 29, 2011
MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cellsNerea Bitarte, Eva Bandres, Valentina Boni, et al.
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Investigational New Drugs|November 23, 2016
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumorsLuis Paz-Ares, Martin Forster, Valentina Boni, et al.
Cancers|July 24, 2021
Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast CancerJosé Manuel López-Vega, Isabel Álvarez, Antonio Antón, et al.
The Oncologist|September 15, 2021
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 TrialAnna Minchom, Aaron C Tan, Erminia Massarelli, et al.
Pageof 7